These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 31375450)

  • 1. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis.
    Chu HH; Kim JH; Yoon HK; Ko HK; Gwon DI; Kim PN; Sung KB; Ko GY; Kim SY; Park SH
    J Vasc Interv Radiol; 2019 Oct; 30(10):1533-1543. PubMed ID: 31471190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
    Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
    Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
    Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
    J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 8. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study.
    Habibollahi P; Shamchi SP; Choi JM; Gade TP; Stavropoulos SW; Hunt SJ; Dagli M; Sudheendra D; Mondschein JI; Soulen MC; Nadolski GJ
    J Vasc Interv Radiol; 2019 Mar; 30(3):323-329. PubMed ID: 30819472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.
    Na SK; Choi GH; Lee HC; Shin YM; An J; Lee D; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
    PLoS One; 2018; 13(6):e0198138. PubMed ID: 29879137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional Chemoembolization Plus Radiofrequency Ablation versus Surgical Resection for Single, Medium-Sized Hepatocellular Carcinoma: Propensity-Score Matching Analysis.
    Lee HJ; Kim JW; Hur YH; Cho SB; Lee BC; Lee BK; Hwang EC; Cho YS; Seon HJ
    J Vasc Interv Radiol; 2019 Mar; 30(3):284-292.e1. PubMed ID: 30819467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
    Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
    BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
    Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
    J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.
    White J; Carolan-Rees G; Dale M; Patrick HE; See TC; Bell JK; Manas DM; Crellin A; Slevin NJ; Sharma RA
    J Vasc Interv Radiol; 2019 Aug; 30(8):1185-1192. PubMed ID: 31255499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm.
    Kim HC; Kim YJ; Lee JH; Suh KS; Chung JW
    J Vasc Interv Radiol; 2019 Jan; 30(1):1-8. PubMed ID: 30293734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.